TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$350 Million

Areteia Therapeutics, Inc.

Private Placement

Exclusive Placement Agent, July 2022

Series A Private Placement

Areteia Therapeutics is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.

More Like This

Feb 2021
$25 Million

Private Placement

Placement Agent

View Details
Jan 2021
$70 Million

Private Placement

Capital Markets Advisor

View Details
Dec 2020
$336 Million

Initial Public Offering and Concurrent Private Placement


View Details